Sheets Smith Wealth Management’s TransCode Therapeutics RNAZ Stock Holding History

Sheets Smith Wealth Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-54	Closed	-$28.6K	–	395
2024 Q3	$28.6K	Buy	54 +32	+145%	+$12.9K	﹤0.01%	371
2024 Q2	$20.2K	Buy	+22	New	+$19.6K	﹤0.01%	373
2023 Q2	–	Hold	0	–	-$20.3K	–	341
2023 Q1	–	Hold	0	–	–	–	314
2022 Q4	–	Hold	0	–	–	–	308

Other funds holding RNAZ

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Sheets Smith Wealth Management's RNAZ Position: Q4 2024 in Review

Sheets Smith Wealth Management sold out of TransCode Therapeutics (RNAZ) in Q4 2024, closing a stake of 54 shares — an estimated $28.6K sold.

Sheets Smith Wealth Management first reported a position in RNAZ in Q2 2024 and held it in 2 quarters. The position peaked at $28.6K in Q3 2024. 3 funds tracked by Wall St. Rank hold RNAZ as of Q4 2024.

Sheets Smith Wealth Management reported no remaining TransCode Therapeutics position as of Q4 2024 after selling out during the quarter.
Sheets Smith Wealth Management sold 54 TransCode Therapeutics shares in Q4 2024, an estimated $28.6K.
Sheets Smith Wealth Management first reported a position in TransCode Therapeutics in Q2 2024 and held it in 2 quarters.
Sheets Smith Wealth Management's TransCode Therapeutics position peaked at $28.6K in Q3 2024.
3 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2024.

Based on Sheets Smith Wealth Management's 13F filing for Q4 2024, filed 17 Jan 2025.